BioMarin Pharmaceutical Inc.

BMRN Healthcare Biotechnology

BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024. In the quarter to June 2026, revenue grew 19.9%, EPS fell 81.6%, free cash flow fell 20.3% and total debt rose 602.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

54.68 1.37 −2.44%
Market cap
$10.9B
P/E
144×
Fwd P/E
16.1×
Dividend yield
—
F-score
5/9
Altman Z
5.67
Beneish M
−2.49
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 0.00 18.58 0.00 130.66 110.17 29.21 32.65
Piotroski F-Score
4 4 6 6 4 4 8 6 8 5
P/S ratio
12.76 12.09 10.11 8.88 8.52 8.75 8.89 7.61 4.38 3.54
Altman Z-Score
5.94 5.25 6.32 5.83 5.93 5.96 7.14 6.38 6.68 5.67
P/FCF ratio
0.00 697.39 298.03 0.00 1,056.63 87.18 126.21 356.59 25.73 15.90
Altman Z″-Score (non-manufacturers)
1.34 2.41 2.97 2.16 4.02 3.87 4.72 4.34 7.30 7.43
Beneish M-Score
(2.74) (2.58) (2.26) (2.39) (1.55) (2.93) (2.33) (2.14) (2.44) (2.49)
P/Operating CF
(67,848.34) 1,086.50 305.36 263.99 (1,184.60) 1,444.99 2,746.77 670.13 67.29 114.39
P/B ratio
5.15 5.65 5.08 4.85 3.86 3.79 4.05 3.72 2.21 1.87
Price to Tangible BV
7.07 7.58 6.62 6.13 4.54 4.39 4.58 4.13 2.40 2.01
EV/Sales
12.66 11.92 10.19 8.94 8.53 8.79 8.80 7.62 4.36 3.39
EV/EBITDA
0.00 205.36 0.00 5,358.31 254.84 526.05 69.33 65.60 21.74 22.57
EV/Operating CF
(62.07) (1,787.89) 752.03 315.61 185.98 53.29 104.84 115.73 21.72 13.20
EV/FCF
(40.24) 687.66 300.41 (168.97) 1,058.08 87.58 124.87 356.84 25.63 15.24
Quick Ratio
2.29 2.03 2.73 1.21 3.07 2.54 2.98 1.45 2.96 3.25
Current Ratio
3.24 2.70 3.93 2.08 4.76 4.16 4.67 2.51 5.33 5.21
Net Debt/EBITDA
0.15 (2.91) 9.23 33.17 0.35 2.44 (0.75) 0.05 (0.95) (1.99)
Debt/Assets
16.98% 25.35% 18.76% 18.08% 18.59% 18.14% 17.15% 15.89% 8.52% 7.86%
Debt/Equity
0.25 0.42 0.28 0.27 0.26 0.26 0.24 0.22 0.11 0.10
Asset Turnover
0.29 0.30 0.33 0.37 0.35 0.31 0.34 0.37 0.41 0.44
Operating CF/Net income
0.36 0.07 (0.26) (2.02) 0.10 (4.75) 1.24 0.95 1.34 2.37
Capex/Depreciation
(1.51) (0.82) (0.99) (1.34) (0.67) (1.05) (0.27) (1.13) (0.99) (1.48)
Interest Coverage
(20.34) (0.34) (2.83) (4.28) (1.48) (5.37) 10.08 10.72 38.23 37.57
ROE
(24.39%) (4.20%) (2.67%) (0.78%) 23.63% (1.53%) 3.19% 3.51% 8.05% 5.94%
ROA
(16.26%) (2.70%) (1.70%) (0.52%) 16.21% (1.08%) 2.29% 2.54% 6.17% 4.79%
ROIC
(18.88%) (0.36%) (2.84%) (1.95%) (0.66%) (1.19%) 2.28% 2.34% 5.92% 5.00%
Return on Tangible Assets
(35.38%) (5.12%) (3.11%) (1.18%) 29.63% (2.32%) 4.37% 5.89% 11.64% 8.41%
Average Days of Receivables
70.36 72.62 83.87 80.84 87.96 73.82 80.33 95.61 84.48 102.91
Research and Development Expense of Revenue
59.27% 46.49% 46.70% 41.96% 33.76% 34.06% 30.99% 30.87% 26.18% 28.62%
Selling, General and Administrative Expense of Revenue
42.67% 42.20% 40.53% 39.96% 39.65% 41.13% 39.28% 36.89% 35.36% 35.79%
Intangible Assets out of Total Assets
0.19 0.15 0.16 0.14 0.10 0.10 0.08 0.07 0.06 0.05
Share Based Compensation of Revenue
12.06% 10.68% 9.98% 9.38% 10.20% 10.68% 9.37% 8.56% 7.06% 5.63%
Graham Net Nets
0.01 0.02 0.04 0.02 0.04 0.03 0.05 0.06 0.15 0.21
Graham Number
0.00 0.00 0.00 0.00 49.11 0.00 20.75 22.98 38.82 36.05
Earnings Yield
(4.58%) (0.73%) (0.50%) (0.17%) 5.38% (0.40%) 0.77% 0.91% 3.42% 3.06%
Free Cash Flow Yield
(2.47%) 0.14% 0.34% (0.60%) 0.09% 1.15% 0.79% 0.28% 3.89% 6.29%
Revenue per Share
6.73 7.53 8.42 9.52 10.29 10.10 11.31 12.88 15.02 16.80
Operating CF per Share
(1.37) (0.05) 0.11 0.27 0.47 1.67 0.95 0.85 3.01 4.32
Capex per Share
(0.89) (0.43) (0.53) (0.77) (0.39) (0.65) (0.15) (0.57) (0.46) (0.58)
Free Cash Flow per Share
(2.27) (0.48) (0.42) (0.50) 0.08 1.01 0.80 0.28 2.55 3.74
Cash per Share
4.76 8.00 6.12 4.21 5.89 5.54 6.97 5.72 5.99 8.14
Shareholders Equity per Share
16.67 16.10 16.76 17.44 22.71 23.33 24.85 26.36 29.77 31.74
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
16.67 16.10 16.76 17.44 22.71 23.33 24.85 26.36 29.77 31.74
Free Cash Flow
(376.22) (82.98) (74.41) (90.14) 15.01 185.31 147.69 51.65 485.42 717.02
Working Capital
982.48 1,390.63 1,532.97 1,009.64 1,849.67 1,727.89 2,162.57 1,779.06 2,625.44 3,194.46
Capital Expenditures
(148.38) (74.22) (94.62) (138.41) (70.36) (119.22) (28.21) (107.61) (87.42) (110.97)
Net Current Asset Value
164.38 382.68 597.03 374.49 600.20 535.28 979.54 1,066.03 1,901.48 2,446.47
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 114.56 99.21 25.70 26.69
Capex to Sales
0.13 0.06 0.06 0.08 0.04 0.06 0.01 0.04 0.03 0.03
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 115.79 99.14 25.80 27.84
Other line items
Depreciation/Fixed assets
0.12 0.10 0.10 0.10 0.10 0.11 0.10 0.09 0.08 0.08
Cash ROIC
(8.87%) (1.54%) (1.52%) (1.91%) 0.24% 2.91% 2.11% 0.73% 6.57% 8.70%
Accounts Receivable Turnover
5.87 5.51 4.94 4.73 4.51 4.49 5.02 4.42 4.41 4.11
Accounts Payable Turnover
0.55 0.63 0.75 0.71 0.99 0.95 0.94 0.85 0.90 1.05
Inventory Turnover
0.67 0.58 0.63 0.59 0.76 0.64 0.60 0.53 0.50 0.57
Average Days of Payables
645.14 606.74 506.28 579.41 342.91 386.53 415.75 468.65 381.83 386.16
Days of Inventory on Hand
618.36 718.23 614.62 690.75 486.33 602.50 648.76 759.54 775.41 660.81
Average Receivables
190.12 238.32 302.00 360.02 412.88 410.88 417.36 547.51 647.12 784.37
Average Payables
381.51 386.21 419.61 503.96 531.58 495.41 535.61 628.05 645.07 683.01
Average Inventory
313.40 415.45 503.32 605.57 689.41 737.61 835.38 1,000.63 1,169.92 1,265.77
Average Assets
3,876.53 4,328.41 4,530.13 4,558.58 5,269.03 5,926.40 6,189.92 6,608.34 6,915.27 7,291.48
Average Common Equity
2,583.56 2,787.47 2,888.30 3,045.16 3,614.19 4,185.84 4,434.41 4,777.35 5,304.77 5,872.49

Fold the line items

Columns are period end dates